PTCT · XBRL financial data

PTC Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PTCT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	381	539	699	938	807	1,731
Research and development	478	541	651	667	534	455
Selling, general and administrative	245	286	326	333	301	347
Total operating expenses	813	913	1,146	1,377	1,109	864
Operating income (loss)	(432)	(374)	(447)	(440)	(303)	867
Other income (expense)	85	(58)	(49)	10	7	(18)
Income tax expense (benefit)	35	6	(28)	(70)	0	14
Net income (loss)	(438)	(524)	(559)	(627)	(363)	683
Earnings per share, basic USD per share	(6.64)	(7.43)	(7.79)	(8.37)	(4.73)	8.58
Earnings per share, diluted USD per share	(6.64)	(7.43)	(7.79)	(8.37)	(4.73)	7.78
Weighted average shares, basic millions of shares	66	70	72	75	77	80
Weighted average shares, diluted millions of shares	66	70	72	75	77	88

Fiscal years (PTCT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	209	190	280	594	780	985
Marketable securities	895	584	131	283	360	961
Inventory	19	16	22	31	23	80
Prepaid and other current assets	39	55	106	150	44	67
Total current assets	1,232	954	694	1,219	1,366	2,274
Property and equipment, net	34	53	73	87	61	55
Right-of-use asset	84	77	102	92	57	80
Goodwill	82	82	82	82	82	82
Total assets	2,208	1,938	1,706	1,896	1,705	2,899
Accounts payable	19	23	27	6	17	45
Current portion of long-term debt	—	150	—	—	—	287
Total current liabilities	277	509	406	603	581	968
Long-term debt	309	282	572	284	285	—
Lease liability, non-current	79	74	101	98	75	94
Total liabilities	1,726	1,937	2,053	2,714	2,803	3,104
Accumulated deficit	(1,629)	(2,098)	(2,657)	(3,284)	(3,647)	(2,964)
Total stockholders' equity	482	1	(347)	(819)	(1,098)	(205)
Total liabilities and equity	2,208	1,938	1,706	1,896	1,705	2,899
Common shares outstanding (cover page) millions of shares	70	71	74	77	79	83

Fiscal years (PTCT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(438)	(524)	(559)	(627)	(363)	683
Stock-based compensation	70	104	110	102	75	75
Depreciation and amortization	43	64	129	237	76	39
Net cash from operating activities	(194)	(251)	(357)	(158)	(108)	711
Purchases of property and equipment	18	28	32	28	7	9
Net cash from investing activities	(562)	219	290	(177)	44	(862)
Proceeds from issuing common stock	28	—	—	—	—	—
Net cash from financing activities	669	21	168	646	256	331
Net change in cash	(79)	(19)	99	314	185	203

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
PTC Therapeutics	509	358	(25)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Inhibitor Therapeutics	0.5	not reported	(0.8)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Integrated Biopharma	4.5	not reported	(1.2)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
Oragenics	3.9	not reported	(2.2)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8.3	not reported	(2.4)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	0.2	1.5	0.1*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	0.3	not reported	(1.8)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
MetaVia	13	not reported	(3.8)*	6.6M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Jaguar Health	3.8	1.2	(5.3)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.